• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

37.07 -0.88 (-2.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rapport Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines ↗
May 07, 2026
Via Chartmill
News headline image
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
May 07, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near ↗
April 27, 2026
This Boston-based biotech innovator in CNS disorders just reported significant insider selling amid a year of standout stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
April 21, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
April 01, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
March 16, 2026
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
March 16, 2026
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
March 16, 2026
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
March 16, 2026
Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 10, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
March 09, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
January 07, 2026
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
December 22, 2025
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
December 22, 2025
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 05, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
November 25, 2025
New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on seizure... 
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
November 19, 2025
 
Via Benzinga
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
November 07, 2025
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Rapport Therapeutics Inc (NASDAQ:RAPP) Reports Q3 2025 Earnings Beat and Positive Phase 2a Seizure Data ↗
November 06, 2025
Rapport Therapeutics beats Q3 earnings estimates, reports strong Phase 2a data for its lead drug candidate RAP-219, and has cash into 2029. 
Via Chartmill
Topics Earnings
News headline image
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
November 06, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in Upcoming Investor Conferences
November 05, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 11, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
September 10, 2025
 
Via Benzinga
News headline image
Rapport Announces Pricing of Public Offering of Common Stock
September 09, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
September 09, 2025
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Rapport Announces Proposed Public Offering of Common Stock
September 08, 2025
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-09-08: top gainers and losers in today's session. ↗
September 08, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
September 08, 2025
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap